E
Elias Arkoudis
Researcher at Queen's University Belfast
Publications - 3
Citations - 209
Elias Arkoudis is an academic researcher from Queen's University Belfast. The author has contributed to research in topics: Druggability & Allosteric regulation. The author has an hindex of 3, co-authored 3 publications receiving 155 citations.
Papers
More filters
Journal ArticleDOI
Discovery and characterization of highly potent and selective allosteric USP7 inhibitors
Gerald Gavory,Colin O'Dowd,Matthew Helm,Jakub T. Flasz,Elias Arkoudis,Anthony Dossang,Caroline Hughes,Eamon Cassidy,Keeva McClelland,Ewa Odrzywol,Natalie Page,Oliver Barker,Hugues Miel,Tim Harrison +13 more
TL;DR: The identification, optimization and detailed characterization of highly potent, selective USP7 inhibitors together with their less active, enantiomeric counterparts are described and co-crystal structures of a human DUB enzyme complexed with small-molecule inhibitors are disclosed, revealing a previously undisclosed allosteric binding site.
Journal ArticleDOI
Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors
Colin O'Dowd,Matthew Helm,J. S. Shane Rountree,Jakub T. Flasz,Elias Arkoudis,Hugues Miel,Peter Hewitt,Linda Jordan,Oliver Barker,Caroline Hughes,Ewelina Rozycka,Eamon Cassidy,Keeva McClelland,Ewa Odrzywol,Natalie Page,Stephanie Feutren-Burton,Scarlett Dvorkin,Gerald Gavory,Tim Harrison +18 more
TL;DR: Potent, novel, and selective inhibitors of USP7 have been developed using both rational and structure-guided design enabled by high-resolution cocrystallography, and initial efforts aimed at developing compounds suitable for in vivo experiments are described.
Proceedings ArticleDOI
Abstract LB-257: Discovery and characterization of novel, highly potent and selective USP7 inhibitors
Gerald Gavory,Colin O'Dowd,Keeva McClelland,Ewa Odrzywol,Alan P. Brown,Stephanie Burton,Oliver Barker,Frank Burkamp,Matt Helm,Iain James,Jakub T. Flasz,Elias Arkoudis,Tim Harrison +12 more
TL;DR: The discovery and detailed biochemical and cellular profiling of novel, potent and selective inhibitors of USP7 have drug-like properties and may provide opportunities for the development of new anticancer therapeutics.